MC10 is collaborating with the University of Rochester to advance medical research.
MC10, Inc. the company behind the innovative mhealth wearable device BioStamp nPoint, is collaborating with researchers from the University of Rochester. The collaboration will use MC10’s wearable system for the purpose of advancing methods of assessing Central Nervous System (CNS) diseases.
The research will specifically focus on assessing the disease progression of movement disorders.
BioStamp nPoint is a system of wearable sensors that collects health data. More specifically, according to MC10, it is an “FDA 510(k) cleared medical device that has been designed to collect medical grade, clinical quality bio-metric, physiological and eCOA data in a clinical trial setting.”
The system collects and processes raw data, displaying it as vital signs, sEMG, sleep metrics, and activity/actigraphy and posture classification. The rechargeable and reusable mobile sensors are multi-location and multi-modal.
For the purpose of the collaborative research with University of Rochester, the press release announcing the collaboration says that the system will be utilized to gather continuous data. This will allow researchers to create algorithms that can provide quantitative assessment of disease progression, specifically for movement disorders.
“Movement disorders such as Huntington’s and Parkinson’s disease represent a therapeutic area that lacks objective, quantitative understanding of disease progression, and therapeutic efficacy,” stated Dr. Arthur Combs, MD, Chief Medical Officer of MC10, in the press release.
“The goals of this research collaboration are to enhance the way we assess people with CNS diseases, improve the way therapies are evaluated, and transform the way these patients are managed toward better outcomes.”
The researchers’ hope is to gather a more complete and accurate data set with the BioStamp nPoint system.
This isn’t the first time that MC10 and the University of Rochester have collaborated on research that is primarily focused on Central Nervous System developments.
That being said, the upcoming research will use more advanced technology and a larger sample size of participants to obtain a more complete and accurate data set. This will reportedly allow for more robust algorithms as well as the development of new digital biomarkers.
It is the hope of MC10 that the newly created algorithms and the insights that are gained throughout the research will better the understanding of movement disorder progression. They also hope it will benefit many of the early adopters of BioStamp nPoint.